Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind Phase 2b Clinical Trial to Investigate the Efficacy and Safety of SP-8203 in Patients With Acute Ischemic Stroke Requiring Recombinant Tissue Plasminogen Activator (rtPA) Standard of Care

NCT04479449 is registered in ClinicalTrials.gov with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04479449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04479449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind Phase 2b Clinical Trial to Investigate the Efficacy and Safety of SP-8203 in Patients With Acute Ischemic Stroke Requiring Recombinant Tissue Plasminogen Activator (rtPA) Standard of Care
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 18, 2019
Completion date
December 18, 2020
Enrollment
178 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke